Mechanistic review of drug-induced steatohepatitis

Toxicology and Applied Pharmacology

Volumn 289, Issue 1, 2015, Pages 40-47

  Schumacher, Justin D ^a   Guo, Grace L ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Carnitine palmitoyltransferase I; Cationic amphiphilic drugs; Chemotherapy associated steatohepatitis; Drug induced steatohepatitis; Mitochondrial toxicity

Indexed keywords

AMIODARONE; DNA TOPOISOMERASE; IRINOTECAN; METHOTREXATE; MITOCHONDRIAL DNA; OXALIPLATIN; PERHEXILINE; TAMOXIFEN; TETRACYCLINE; VALPROIC ACID; CAMPTOTHECIN; PLATINUM COMPLEX;

CHEMOTHERAPY ASSOCIATED STEATOHEPATITIS; DRUG INDUCED DISEASE; DRUG INDUCED STEATOHEPATITIS; FATTY ACID SYNTHESIS; HUMAN; LIVER CELL; LYSOSOME; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHOSPHOLIPID METABOLISM; REVIEW; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FATTY LIVER; LIPID METABOLISM; LIVER; LIVER MITOCHONDRION; METABOLISM; PATHOLOGY; TOXIC HEPATITIS;

AMIODARONE; ANIMALS; CAMPTOTHECIN; CHEMICAL AND DRUG INDUCED LIVER INJURY; DISEASE MODELS, ANIMAL; FATTY LIVER; HEPATOCYTES; HUMANS; LIPID METABOLISM; LIVER; METHOTREXATE; MITOCHONDRIA, LIVER; ORGANOPLATINUM COMPOUNDS; PERHEXILINE; TAMOXIFEN; TETRACYCLINE; VALPROIC ACID;

EID: 84945485781     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2015.08.022     Document Type: Review

References (67)

1. Aires C.C., Ruiter J.P., Luis P.B., ten Brink H.J., Ijlst L., de Almeida I.T., Duran M., Wanders R.J., Silva M.F. Studies on the extra-mitochondrial CoA-ester formation of valproic and Delta4-valproic acids. Biochim. Biophys. Acta 2007, 1771:533-543.
2. Aires C.C., Ijlst L., Stet F., Prip-Buus C., de Almeida I.T., Duran M., Wanders R.J., Silva M.F. Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis. Biochem. Pharmacol. 2010, 79:792-799.
3. Aithal G.P., Haugk B., Das S., Card T., Burt A.D., Record C.O. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?. Aliment. Pharmacol. Ther. 2004, 19:391-399.
4. Antherieu S., Rogue A., Fromenty B., Guillouzo A., Robin M.A. Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells. Hepatology (Baltimore, Md.) 2011, 53:1895-1905.
5. Arena U., Stasi C., Mannoni A., Benucci M., Maddali-Bongi S., Cammelli D., Assarat A., Marra F., Pinzani M. Liver stiffness correlates with methotrexate cumulative dose in patients with rheumatoid arthritis. Dig. Liver Dis. 2012, 44:149-153.
6. Barclay M.L., Sawyers S.M., Begg E.J., Zhang M., Roberts R.L., Kennedy M.A., Elliott J.M. Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics 2003, 13:627-632.
7. Bendirdjian J.P., Viotte G., Bichara M., Foucher B., Fillastre J.P. Changes in the lysosomes and mitochondria isolated from the liver, kidney and heart of rats treated with perhexiline maleate. Toxicol. Eur. Res. 1982, 4:297-300.
8. Bieghs V., Rensen P.C., Hofker M.H., Shiri-Sverdlov R. NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages. Atherosclerosis 2012, 220:287-293.
9. Bjornsson E., Lindberg J., Olsson R. Liver reactions to oral low-dose tetracyclines. Scand. J. Gastroenterol. 1997, 32:390-395.
10. Bruning A., Brem G.J., Vogel M., Mylonas I. Tetracyclines cause cell stress-dependent ATF4 activation and mTOR inhibition. Exp. Cell Res. 2014, 320:281-289.
11. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander-Tetri B.A., Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999, 94:2467-2474.
12. Campbell S.E., Mehan K.A., Tunstall R.J., Febbraio M.A., Cameron-Smith D. 17beta-estradiol upregulates the expression of peroxisome proliferator-activated receptor alpha and lipid oxidative genes in skeletal muscle. J. Mol. Endocrinol. 2003, 31:37-45.
13. Casademont J., Garrabou G., Miro O., Lopez S., Pons A., Bernardo M., Cardellach F. Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients. J. Clin. Psychopharmacol. 2007, 27:284-288.
14. Chan E.S., Montesinos M.C., Fernandez P., Desai A., Delano D.L., Yee H., Reiss A.B., Pillinger M.H., Chen J.F., Schwarzschild M.A., Friedman S.L., Cronstein B.N. Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. Br. J. Pharmacol. 2006, 148:1144-1155.
15. Chen J.Q., Delannoy M., Cooke C., Yager J.D. Mitochondrial localization of ERalpha and ERbeta in human MCF7 cells. Am. J. Physiol. Endocrinol. Metab. 2004, 286:E1011-E1022.
16. Costa M.L., Lima-Junior R.C., Aragao K.S., Medeiros R.P., Marques-Neto R.D., de Sa Grassi L., Leite L.L., Nunes L.G., de Mesquita Neto J.W., de Castro Brito G.A., de Souza M.H., de Almeida P.R., Ribeiro R.A. Chemotherapy-associated steatohepatitis induced by irinotecan: a novel animal model. Cancer Chemother. Pharmacol. 2014, 74:711-720.
17. Cronstein B.N., Eberle M.A., Gruber H.E., Levin R.I. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:2441-2445.
18. Day C.P., James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998, 114:842-845.
19. Deng Z., Yan S., Hu H., Duan Z., Yin L., Liao S., Sun Y., Yin D., Li G. Proteomic profile of carbonylated proteins in rat liver: Discovering possible mechanisms for tetracycline-induced steatosis. Proteomics 2015, 15:148-159.
20. Deschamps D., DeBeco V., Fisch C., Fromenty B., Guillouzo A., Pessayre D. Inhibition by perhexiline of oxidative phosphorylation and the beta-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions. Hepatology (Baltimore, Md.) 1994, 19:948-961.
21. FDA FDA Drug Safety Communication: Severe liver injury associated with the use of dronedarone (marketed as Multaq) 2011.
22. Felser A., Blum K., Lindinger P.W., Bouitbir J., Krahenbuhl S. Mechanisms of hepatocellular toxicity associated with dronedarone - a comparison to amiodarone. J. Toxicol. Sci. 2013, 131:480-490.
23. Felser A., Stoller A., Morand R., Schnell D., Donzelli M., Terracciano L., Bouitbir J., Krahenbuhl S. Hepatic toxicity of dronedarone in mice: role of mitochondrial beta-oxidation. Toxicology 2014, 323:1-9.
24. Fernandez F.G., Ritter J., Goodwin J.W., Linehan D.C., Hawkins W.G., Strasberg S.M. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J. Am. Coll. Surg. 2005, 200:845-853.
25. Fisar Z. Interactions between tricyclic antidepressants and phospholipid bilayer membranes. Gen. Physiol. Biophys. 2005, 24:161-180.
26. Freneaux E., Labbe G., Letteron P., The Le D., Degott C., Geneve J., Larrey D., Pessayre D. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology (Baltimore, Md.) 1988, 8:1056-1062.
27. Fromenty B., Fisch C., Labbe G., Degott C., Deschamps D., Berson A., Letteron P., Pessayre D. Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J. Pharmacol. Exp. Ther. 1990, 255:1371-1376.
28. Geneve J., Hayat-Bonan B., Labbe G., Degott C., Letteron P., Freneaux E., Dinh T.L., Larrey D., Pessayre D. Inhibition of mitochondrial beta-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this nonsteroidal anti-inflammatory drug. J. Pharmacol. Exp. Ther. 1987, 242:1133-1137.
29. Hamminga E.A., van der Lely A.J., Neumann H.A., Thio H.B. Chronic inflammation in psoriasis and obesity: implications for therapy. Med. Hypotheses 2006, 67:768-773.
30. Hostetler K.Y., Reasor M., Yazaki P.J. Chloroquine-induced phospholipid fatty liver. Measurement of drug and lipid concentrations in rat liver lysosomes. J. Biol. Chem. 1985, 260:215-219.
31. Huang C., Hsu P., Hung Y., Liao Y., Liu C., Hour C., Kao M., Tsay G.J., Hung H., Liu G.Y. Ornithine decarboxylase prevents methotrexate-induced apoptosis by reducing intracellular reactive oxygen species production. Apoptosis 2005, 10:895-907.
32. Joghetaei N., Weirich G., Huber W., Buchler P., Estner H. Acute liver failure associated with dronedarone. Circ. Arrhythm. Electrophysiol. 2011, 4:592-593.
33. Kennedy J.A., Unger S.A., Horowitz J.D. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem. Pharmacol. 1996, 52:273-280.
34. Kesterson J.W., Granneman G.R., Machinist J.M. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology (Baltimore, Md.) 1984, 4:1143-1152.
35. Kim J.S., Lowe K.E., Shane B. Regulation of folate and one-carbon metabolism in mammalian cells. IV. Role of folylpoly-gamma-glutamate synthetase in methotrexate metabolism and cytotoxicity. J. Biol. Chem. 1993, 268:21680-21685.
36. Kosovsky M.J., Soslau G. Immunological identification of human platelet mitochondrial DNA topoisomerase I. Biochim. Biophys. Acta 1993, 1164:101-107.
37. Kremer J.M., Galivan J., Streckfuss A., Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum. 1986, 29:832-835.
38. Larosche I., Letteron P., Fromenty B., Vadrot N., Abbey-Toby A., Feldmann G., Pessayre D., Mansouri A. Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver. J. Pharmacol. Exp. Ther. 2007, 321:526-535.
39. Le Dinh T., Freneaux E., Labbe G., Letteron P., Degott C., Geneve J., Berson A., Larrey D., Pessayre D. Amineptine, a tricyclic antidepressant, inhibits the mitochondrial oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J. Pharmacol. Exp. Ther. 1988, 247:745-750.
40. Leli U., Hauser G. Modifications of phospholipid metabolism induced by chlorpromazine, desmethylimipramine and propranolol in C6 glioma cells. Biochem. Pharmacol. 1987, 36:31-37.
41. Letteron P., Sutton A., Mansouri A., Fromenty B., Pessayre D. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology (Baltimore, Md.) 2003, 38:133-140.
42. Maher A.C., Akhtar M., Tarnopolsky M.A. Men supplemented with 17beta-estradiol have increased beta-oxidation capacity in skeletal muscle. Physiol. Genomics 2010, 42:342-347.
43. Mesens N., Desmidt M., Verheyen G.R., Starckx S., Damsch S., De Vries R., Verhemeldonck M., Van Gompel J., Lampo A., Lammens L. Phospholipidosis in rats treated with amiodarone: serum biochemistry and whole genome micro-array analysis supporting the lipid traffic jam hypothesis and the subsequent rise of the biomarker BMP. Toxicol. Pathol. 2012, 40:491-503.
44. Pessayre D., Fromenty B., Berson A., Robin M.A., Letteron P., Moreau R., Mansouri A. Central role of mitochondria in drug-induced liver injury. Drug Metab. Rev. 2012, 44:34-87.
45. Pfizer Cordarone (amiodarone hydrochloride)[Package Insert] 2014.
46. Ponchaut S., van Hoof F., Veitch K. In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA sequestration to the observed inhibitions. Biochem. Pharmacol. 1992, 43:2435-2442.
47. Rosenberg P., Urwitz H., Johannesson A., Ros A.M., Lindholm J., Kinnman N., Hultcrantz R. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J. Hepatol. 2007, 46:1111-1118.
48. Sanofi-Aventis Multaq (dronedarone)[Package Insert] 2014.
49. Serviddio G., Bellanti F., Giudetti A.M., Gnoni G.V., Capitanio N., Tamborra R., Romano A.D., Quinto M., Blonda M., Vendemiale G., Altomare E. Mitochondrial oxidative stress and respiratory chain dysfunction account for liver toxicity during amiodarone but not dronedarone administration. Free Radic. Biol. Med. 2011, 51:2234-2242.
50. Shaikh N.A., Downar E., Butany J. Amiodarone-an inhibitor of phospholipase activity: a comparative study of the inhibitory effects of amiodarone, chloroquine and chlorpromazine. Mol. Cell. Biochem. 1987, 76:163-172.
51. Silva M.F., Ruiter J.P., L, I.J., Jakobs C., Duran M., de Almeida I.T., Wanders R.J. Differential effect of valproate and its Delta2- and Delta4-unsaturated metabolites, on the beta-oxidation rate of long-chain and medium-chain fatty acids. Chem. Biol. Interact. 2001, 137:203-212.
52. Silva M.F., Aires C.C., Luis P.B., Ruiter J.P., L, I.J., Duran M., Wanders R.J., Tavares de Almeida I. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J. Inherit. Metab. Dis. 2008, 31:205-216.
53. Sommer D.M., Jenisch S., Suchan M., Christophers E., Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch. Dermatol. Res. 2006, 298:321-328.
54. Song D., Shi B., Xue H., Li Y., Yang X., Yu B., Xu Z., Liu F., Li J. Confirmation and prevention of intestinal barrier dysfunction and bacterial translocation caused by methotrexate. Dig. Dis. Sci. 2006, 51:1549-1556.
55. Spaniol M., Bracher R., Ha H.R., Follath F., Krahenbuhl S. Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. J. Hepatol. 2001, 35:628-636.
56. Szalowska E., van der Burg B., Man H.Y., Hendriksen P.J., Peijnenburg A.A. Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices. PLoS One 2014, 9.
57. Tabassum H., Parvez S., Pasha S.T., Banerjee B.D., Raisuddin S. Protective effect of lipoic acid against methotrexate-induced oxidative stress in liver mitochondria. Food Chem. Toxicol. 2010, 48:1973-1979.
58. Tuquet C., Dupont J., Mesneau A., Roussaux J. Effects of tamoxifen on the electron transport chain of isolated rat liver mitochondria. Cell Biol. Toxicol. 2000, 16:207-219.
59. Vauthey J.N., Pawlik T.M., Ribero D., Wu T.T., Zorzi D., Hoff P.M., Xiong H.Q., Eng C., Lauwers G.Y., Mino-Kenudson M., Risio M., Muratore A., Capussotti L., Curley S.A., Abdalla E.K. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J. Clin. Oncol. 2006, 24:2065-2072.
60. Wang W., Lin R., Zhang J., Mao Y., Bu X., Ji Q., Zhai X., Lin Q., Yang L., Zhang K. Involvement of fatty acid metabolism in the hepatotoxicity induced by divalproex sodium. Hum. Exp. Toxicol. 2012, 31:1092-1101.
61. Wang C., Li H., Meng Q., Du Y., Xiao F., Zhang Q., Yu J., Li K., Chen S., Huang Z., Liu B., Guo F. ATF4 deficiency protects hepatocytes from oxidative stress via inhibiting CYP2E1 expression. J. Cell. Mol. Med. 2014, 18:80-90.
62. Xiao G., Zhang T., Yu Shibing, Lee S., Calabuig-Navarro V., Yamauchi J., Ringquist S., Dong H. ATF4 deficiency protects against high fructose-induced hypertriglyceridemia in mice. J. Biol. Chem. 2013, 288:25350-25361.
63. Zachariae H., Kragballe K., Sogaard H. Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment. Br. J. Dermatol. 1980, 102:407-412.
64. Zhang D., Liu Z.X., Choi C.S., Tian L., Kibbey R., Dong J., Cline G.W., Wood P.A., Shulman G.I. Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:17075-17080.
65. Zhang X., Fryknas M., Hernlund E., Fayad W., De Milito A., Olofsson M.H., Gogvadze V., Dang L., Pahlman S., Schughart L.A., Rickardson L., D'Arcy P., Gullbo J., Nygren P., Larsson R., Linder S. Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nat. Commun. 2014, 5:3295.
66. Zhao F., Xie P., Jiang J., Zhang L., An W., Zhan Y. The effect and mechanism of tamoxifen-induced hepatocyte steatosis in vitro. Int. J. Mol. Sci. 2014, 15:4019-4030.
67. Zhou Z., Zhou J., Du Y. Estrogen receptor alpha interacts with mitochondrial protein HADHB and affects beta-oxidation activity. Mol. Cell. Proteomics 2012, 11.